Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

- PMLiVE

Beyond the injection: why the real work of weight loss starts where the drug leaves off

Behaviour change is not primarily a matter of information or intention, but of habit, environment, identity and reward

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE

Envision appoints Darren Coleman as Executive VP, Chief Information Officer

Coleman previously held senior leadership positions at Syneos Health and AI One

- PMLiVE

AL-S Pharma release new data from AP-101 phase 2 trial for ALS

ALS is a progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord

- PMLiVE

Envision appoints Jay Ferro as President, Technology and Chief Product Officer

Ferro was previously EVP, Chief Information, Technology & Product Officer at Clario

- PMLiVE

A simplified three-step process for achieving the fundamentals of omnichannel engagement in pharma: how to deliver impactful, connected experiences

By Aaron Fletcher

Amiculum

- PMLiVE

Grifols share results identifying early signs of Parkinson’s disease

Parkinson’s disease affects over six million people globally

- PMLiVE

Richmond Pharmacology appoints John Hotti as Chief Technology Officer

Hotti was previously Head of AI and CIO at Telrock Systems

- PMLiVE

Beyond the Linear Path: Leading with Your Full Self

Listen to the full episode here. In the latest episode of the Hear From Her podcast, Giulia Ghibellini (Teva Pharmaceuticals) and Professor Amanda Kirby (Do-IT Solutions) share how their experiences...

Medscape Education

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links